Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Duality Biotherapeutics, Inc. ( (HK:9606) ) has shared an announcement.
Duality Biotherapeutics, Inc. has announced a board meeting scheduled for August 26, 2025, to consider and approve the company’s unaudited interim results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$270.34 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a company incorporated in the Cayman Islands, focusing on the biotherapeutics industry. It is listed on the Stock Exchange of Hong Kong and is involved in developing innovative therapeutic solutions.
Average Trading Volume: 280,970
Current Market Cap: HK$30.97B
See more data about 9606 stock on TipRanks’ Stock Analysis page.